Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.94M | 37.93M | 37.68M | 36.19M | 33.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 306.35M | 285.42M | 269.27M | 234.18M | 204.07M |
| Operating Income | -306.35M | -285.42M | -269.27M | -234.18M | -204.07M |
| Income Before Tax | -269.44M | -252.06M | -237.22M | -204.18M | -179.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -269.44 | -252.06 | -237.22 | -204.18 | -179.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -269.44M | -252.06M | -237.22M | -204.18M | -179.27M |
| EBIT | -306.35M | -285.42M | -269.27M | -234.18M | -204.07M |
| EBITDA | -306.33M | -285.41M | -269.27M | -234.17M | -204.05M |
| EPS Basic | -3.75 | -3.75 | -3.75 | -3.41 | -3.20 |
| Normalized Basic EPS | -2.25 | -2.25 | -2.28 | -2.07 | -1.94 |
| EPS Diluted | -3.75 | -3.75 | -3.75 | -3.41 | -3.20 |
| Normalized Diluted EPS | -2.25 | -2.25 | -2.28 | -2.07 | -1.94 |
| Average Basic Shares Outstanding | 287.83M | 268.48M | 253.63M | 239.80M | 222.51M |
| Average Diluted Shares Outstanding | 287.83M | 268.48M | 253.63M | 239.80M | 222.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |